Current treatment options for the parasitic disease leishmaniasis are largely ineffective, expensive, and tend to be plagued by resistant parasites and side effects. Now, researchers reporting in PLOS Neglected Tropical Diseases have showed that a natural flavonoid is effective at treating Leishmania amazonensis infections.
Leishmaniasis is endemic to 98 countries and affects more than 12 million people around the world. Treatment is possible with pentavalent antimonial, but many Leishmania parasites have become resistant to antimonial chemotherapy. Flavonoids- a group of natural compounds that are isolated from fruits, vegetables, wine and coffee- have been considered a promising candidate for leishmanisis treatment. 2’-Hydroxyflavanone (2HF), part of a class of flavonoids found in citrus fruits, is already being studied for its use in cancer chemotherapy.
In the new work, Elmo Almeida-Amaral, of the Oswaldo Cruz Foundation, Brazil, and colleagues studied the effect of 2HF on wild-type and antimony-resistant L. amazonensis parasite cells, and then went on to test the effectiveness of the compound in treating mice with L. amazonensis infections.
2HF stopped the proliferation of L. amazonensis parasites in both their free-living form and the form that infects human cells in both strains of L. amazonensis tested. In addition, 2HF reduced the overall number of parasites in an infected mouse, and reduced the size of lesions caused by the cutaneous form of leishmaniasis. No side effects were seen in the treated mice.
“Considering that 2HF reduced the lesion size and parasite load without compromising the overall health of the infected mice, we suggest this compound as a potential candidate for leishmaniasis chemotherapy for cutaneous leishmaniasis,” the researchers say. “Studies should be conducted to determine the ideal dose and therapeutic regimen.”
Source: PLOS
APIC Salutes 2025 Trailblazers in Infection Prevention and Control
June 18th 2025From a lifelong mentor to a rising star, the Association for Professionals in Infection Control and Epidemiology (APIC) honored leaders across the career spectrum at its 2025 Annual Conference in Phoenix, recognizing individuals who enhance patient safety through research, leadership, and daily practice.
Building Infection Prevention Capacity in the Middle East: A 7-Year Certification Success Story
June 17th 2025Despite rapid development, the Middle East faces a critical shortage of certified infection preventionists. A 7-year regional initiative has significantly boosted infection control capacity, increasing the number of certified professionals and elevating patient safety standards across health care settings.
Streamlined IFU Access Boosts Infection Control and Staff Efficiency
June 17th 2025A hospital-wide quality improvement project has transformed how staff access critical manufacturer instructions for use (IFUs), improving infection prevention compliance and saving time through a standardized, user-friendly digital system supported by unit-based training and interdepartmental collaboration.
Swift Isolation Protocol Shields Chicago Children’s Hospital During 2024 Measles Surge
June 17th 2025When Chicago logged its first measles cases linked to crowded migrant shelters last spring, one pediatric hospital moved in hours—not days—to prevent the virus from crossing its threshold. Their playbook offers a ready template for the next communicable-disease crisis.